SCHEMBL22875605

SCHEMBL22875605

CCCCCCCCCCOP(=O)(OCCCCCCCCCC)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RY1 P47900 5/20 0.70
▸ P2RY2 P41231 4/20 0.70
▸ SRC P12931 2/20 0.70
▸ SMN1; SMN2 Q16637 2/20 0.70
▸ TRPM2 O94759 2/20 0.70
▸ TAS1R3 Q7RTX0 2/20 0.70
▸ TAS1R1 Q7RTX1 2/20 0.70
▸ DNPH1 O43598 1/20 0.70
▸ PRKAB2 O43741 1/20 0.70
▸ LDHA P00338 1/20 0.70
▸ ADRB2 P07550 1/20 0.70
▸ FBP1 P09467 1/20 0.70
▸ ADORA1 P30542 1/20 0.70
▸ PRKAG1 P54619 1/20 0.70
▸ PRKAA2 P54646 1/20 0.70
▸ PDE4D Q08499 1/20 0.70
▸ KCNH2 Q12809 1/20 0.70
▸ PRKAA1 Q13131 1/20 0.70
▸ PDE3A Q14432 1/20 0.70
▸ P2RY11 Q96G91 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10792068 0.92 P2RY1 (0.75) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL10792796 0.92 P2RY1 (0.75) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL29859832 0.92 P2RY1 (0.75) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL10790838 0.92 P2RY1 (0.75) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL9985929 0.92 P2RY1 (0.75) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL1270476 0.91 P2RY1 (0.77) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL10521997 0.90 P2RY1 (0.75) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL10522182 0.89 P2RY1 (0.76) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL10520556 0.89 P2RY1 (0.78) P2RY1P2RY2SRCSMN1; SMN2TRPM2
SCHEMBL22875603 0.88 P2RY1 (0.55) P2RY1P2RY2SRCSMN1; SMN2TRPM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210007999-A1 NANOPARTICLE COMPOSITIONS JANUARY THERAPEUTICS, INC. 2021-01-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210007999-A1 NANOPARTICLE COMPOSITIONS PNP, NTPCR, TYMP P2RY1 446/4885P2RY2 1044/4885SRC 1041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback